Video

The Long-Term Impact of Biosimilars

Author(s):

Lauren Santye, Assistant Editor

Douglas Samojedny, RPh, director of Pharmacy Operations at Pharmacy Advantage, discusses how biosimilars could impact specialty pharmacy into the immediate future.

Douglas Samojedny, RPh, director of Pharmacy Operations at Pharmacy Advantage, discusses how biosimilars could impact specialty pharmacy into the immediate future.

Related Videos
California Wildfires, Pharmacies, Community | image Credit: J Bettencourt/peopleimages.com | stock.adobe.com
California Wildfire, Pharmacy, Community | Image Credit: Erin | stock.adobe.com
Allergies, Asthma, Biologic Treatment, Pharmacists | Image Credit: Pixel-Shot | stock.adobe.com
Related Content
These therapies have demonstrated versatile applications across disease states, such as oncology and infectious diseases. | Image Credit: shidlovski | stock.adobe.com
February 1st 2025

Fitusiran Is a Drug to Watch in the Hematology Space in 2025

Ashley Gallagher, Editor
Pharmacy Focus: Oncology Edition - Discussing Increasing Rates of Lung Cancer in Young Adults and Emerging Precision Treatments
November 25th 2024

Pharmacy Focus: Oncology Edition - Discussing Increasing Rates of Lung Cancer in Young Adults and Emerging Precision Treatments

Man experiencing pain in liver -- Image credit: eddows | stock.adobe.com
January 31st 2025

Model Estimates Prevalence of MASLD Will Increase From 33.7% in 2020 to 41.4% in 2050

Gillian McGovern, Associate Editor
Pharmacy Focus: Oncology Edition- Exploring Pelareorep: A Novel Immunotherapy for Advanced Breast Cancer
October 28th 2024

Pharmacy Focus: Oncology Edition- Exploring Pelareorep: A Novel Immunotherapy for Advanced Breast Cancer

Pharmacists educate and counsel patients on effective use of GLP-1 medication. | Image Credit: K KStock | stock.adobe.com
January 31st 2025

Q&A: Pharmacists Play Pivotal Role in Evolving Diabetes Care with New Treatments

Ashley Gallagher, Editor
The drug is indicated for imultiple diseases, such as rheumatoid arthritis (RA), giant cell arteritis, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis, and COVID-19.| Pawel | stock.adobe.com
January 31st 2025

FDA Approves Tocilizumab-Anoh as a Biosimilar to Actemra

Ashley Gallagher, Editor